To investigate the association between GLP-1 receptor agonists (GLP-1 RAs) and specific outcomes, including all-cause mortality and recurrence-free survival, in breast cancer patients.
Key Findings:
GLP-1 RA users had a notable 60% lower all-cause mortality at 5 and 10 years compared to nonusers.
Significant relative increase in RFS among GLP-1 RA users compared to nonusers and insulin/metformin cohorts.
No statistical differences in outcomes were found when comparing GLP-1 RA users with SGLT2 inhibitor users.
Interpretation:
The study suggests a potential survival benefit associated with GLP-1 RAs in breast cancer patients, which could have significant implications for clinical practice, warranting further investigation through randomized clinical trials.
Limitations:
Retrospective design limits causal inference and does not account for duration of GLP-1 RA use or specific medications.
Lack of data on weight loss, diabetes control, and mechanisms underlying survival differences.
Findings may not be generalizable to other cancer types or advanced cancer stages.
Potential biases inherent in retrospective studies may affect the validity of the findings.
Conclusion:
GLP-1 RAs may be beneficial for breast cancer patients, and clinicians should consider prescribing them for early-stage cancer management. However, further research through randomized clinical trials is essential to clarify their role in cancer treatment.
